AVGR Stock - Avinger, Inc.
Unlock GoAI Insights for AVGR
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|
| Revenue | $7.65M | $8.27M | $10.13M | $8.76M | $9.13M |
| Gross Profit | $2.00M | $2.65M | $3.42M | $2.62M | $2.87M |
| Gross Margin | 26.2% | 32.1% | 33.8% | 29.9% | 31.4% |
| Operating Income | $-16,635,000 | $-15,957,000 | $-18,101,000 | $-17,404,000 | $-19,359,000 |
| Net Income | $-18,320,000 | $-17,427,000 | $-20,710,000 | $-19,823,000 | $-19,752,000 |
| Net Margin | -239.4% | -210.6% | -204.4% | -226.3% | -216.3% |
| EPS | $-23.31 | $-41.83 | $-65.79 | $-120.80 | $-818.60 |
Avinger, Inc., a commercial-stage medical device company, designs, manufactures, and sells a suite of image-guided and catheter-based systems used by physicians to treat patients with peripheral arterial disease (PAD) in the United States and internationally. It develops lumivascular platform that integrates optical coherence tomography visualization with interventional catheters to provide real-time intravascular imaging during the treatment portion of PAD procedures. The company's lumivascular products comprise Lightbox imaging consoles, as well as the Ocelot family of catheters, which are designed to allow physicians to penetrate a total blockage in an artery; and Pantheris, an image-guided atherectomy device that allows physicians to precisely remove arterial plaque in PAD patients. In addition, its first-generation chronic total occlusion (CTO)-crossing catheters, Wildcat and Kittycat 2, which employs a proprietary design that uses a rotational spinning technique allowing the physician to switch between passive and active modes when navigating across a CTO. Further, the company develops IMAGE-BTK for the treatment of PAD lesions below-the-knee. It markets and sells its products to interventional cardiologists, vascular surgeons, and interventional radiologists. Avinger, Inc. was incorporated in 2007 and is headquartered in Redwood City, California.
Visit WebsiteEarnings History & Surprises
AVGREPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q4 2025 | Nov 5, 2025 | — | — | — | — |
Q3 2025 | Aug 6, 2025 | — | — | — | — |
Q2 2025 | May 13, 2025 | — | — | — | — |
Q1 2025 | Mar 19, 2025 | $-0.40 | $-3.93 | -882.5% | ✗ MISS |
Q4 2024 | Nov 7, 2024 | $-2.03 | $-1.82 | +10.3% | ✓ BEAT |
Q3 2024 | Aug 8, 2024 | $-0.43 | $-2.82 | -555.8% | ✗ MISS |
Q2 2024 | May 15, 2024 | $-1.35 | $-2.49 | -84.4% | ✗ MISS |
Q1 2024 | Mar 20, 2024 | $0.64 | $-3.93 | -714.1% | ✗ MISS |
Q4 2023 | Oct 26, 2023 | $-2.85 | $-2.92 | -2.5% | ✗ MISS |
Q3 2023 | Jul 27, 2023 | $-7.35 | $-8.85 | -20.4% | ✗ MISS |
Q2 2023 | May 10, 2023 | $-7.35 | $-10.64 | -44.8% | ✗ MISS |
Q1 2023 | Mar 15, 2023 | $-15.15 | $-10.49 | +30.8% | ✓ BEAT |
Q4 2022 | Nov 9, 2022 | $-15.90 | $-11.54 | +27.4% | ✓ BEAT |
Q3 2022 | Aug 11, 2022 | $-16.34 | $-14.09 | +13.8% | ✓ BEAT |
Q2 2022 | May 10, 2022 | $-18.14 | $-34.93 | -92.6% | ✗ MISS |
Q1 2022 | Mar 22, 2022 | $-18.89 | $-18.89 | 0.0% | = MET |
Q4 2021 | Nov 11, 2021 | $-20.99 | $-17.99 | +14.3% | ✓ BEAT |
Q3 2021 | Aug 10, 2021 | $-11.99 | $-11.99 | 0.0% | = MET |
Q2 2021 | May 6, 2021 | $-11.99 | $-20.99 | -75.0% | ✗ MISS |
Q1 2021 | Mar 11, 2021 | $-0.06 | $-20.99 | -34883.3% | ✗ MISS |
Latest News
Frequently Asked Questions about AVGR
What is AVGR's current stock price?
What is the analyst price target for AVGR?
What sector is Avinger, Inc. in?
What is AVGR's market cap?
Does AVGR pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to AVGR for comparison